Join Growin Stock Community!

Labcorp holdings inc.LH.US Overview

US StockHealthcare
(No presentation for LH)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

LH AI Insights

LH Overall Performance

LH AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

LH Recent Performance

-0.92%

Labcorp holdings inc.

0.05%

Avg of Sector

-0.31%

S&P500

LH PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

LH Key Information

LH Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

LH Profile

Laboratory Corporation of America Holdings operates as a global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, and parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. It provides online and mobile applications to enable patients to check test results; and online applications for managed care organizations and accountable care organizations. It offers end-to-end drug development, medical device, and companion diagnostic development solutions from early-stage research to clinical development and commercial market access. It serves managed care organizations, pharmaceutical, biotechnology, medical device and diagnostics companies, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, and independent clinical laboratories. Laboratory Corporation of America Holdings has a collaboration agreement with Tigerlily Foundation to increase clinical trial diversity for women of color. The company was incorporated in 1994 and is headquartered in Burlington, North Carolina.

Price of LH

LH FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

LH Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
10.57
PE Ratio (TTM)
27.61
Forward PE
16.13
PS Ratio (TTM)
1.72
PB Ratio
2.74
Price-to-FCF
19.69
METRIC
VALUE
vs. INDUSTRY
Gross Margin
28.76%
Net Margin
6.28%
Revenue Growth (YoY)
7.25%
Profit Growth (YoY)
10.71%
3-Year Revenue Growth
-1.46%
3-Year Profit Growth
0.80%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
10.57
PE Ratio (TTM)
27.61
Forward PE
16.13
PS Ratio (TTM)
1.72
PB Ratio
2.74
Price-to-FCF
19.69
Gross Margin
28.76%
Net Margin
6.28%
Revenue Growth (YoY)
7.25%
Profit Growth (YoY)
10.71%
3-Year Revenue Growth
-1.46%
3-Year Profit Growth
0.80%

  • When is LH's latest earnings report released?

    The most recent financial report for Labcorp holdings inc. (LH) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating LH's short-term business performance and financial health. For the latest updates on LH's earnings releases, visit this page regularly.

  • Where does LH fall in the P/E River chart?

    According to historical valuation range analysis, Labcorp holdings inc. (LH)'s current price-to-earnings (P/E) ratio is 26.99, placing it in the Reasonable zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of LH?

    According to the latest financial report, Labcorp holdings inc. (LH) reported an Operating Profit of 267.6M with an Operating Margin of 7.61% this period, representing a growth of 23.6% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is LH's revenue growth?

    In the latest financial report, Labcorp holdings inc. (LH) announced revenue of 3.52B, with a Year-Over-Year growth rate of 5.6%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does LH have?

    As of the end of the reporting period, Labcorp holdings inc. (LH) had total debt of 6.53B, with a debt ratio of 0.35. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does LH have?

    At the end of the period, Labcorp holdings inc. (LH) held Total Cash and Cash Equivalents of 532.3M, accounting for 0.03 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does LH go with three margins increasing?

    In the latest report, Labcorp holdings inc. (LH) achieved the “three margins increasing” benchmark, with a gross margin of 28.2%%, operating margin of 7.61%%, and net margin of 4.7%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess LH's profit trajectory and future growth potential.

  • Is LH's EPS continuing to grow?

    According to the past four quarterly reports, Labcorp holdings inc. (LH)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 2. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of LH?

    Labcorp holdings inc. (LH)'s Free Cash Flow (FCF) for the period is 490.3M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 26.28% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.